Anti-Toxoplasma gondii antibodies in hemodialysis patients receiving long-term hemodialysis therapy in Turkey

Basit Öğe Kaydı
dc.authoridGONCALVES DA SILVA, WANIA/0000-0001-7498-7686
dc.contributor.authorOcak, S
dc.contributor.authorDuran, N
dc.contributor.authorEskiocak, AF
dc.contributor.authorAytac, H
dc.date.accessioned2024-09-18T21:07:41Z
dc.date.available2024-09-18T21:07:41Z
dc.date.issued2005
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjectives: Toxoplasma is a globally distributed pathogen for humans and animals. In situations of immunodeficiency, Toxoplasma gondii (T. gondii) emerges as a life-threatening infection. Toxoplasma gondii is transmitted parenterally, flourish in state immunosuppression and, most toxoplasma infections are asymptomatic. In the present study, we aimed to investigate the prevalence of anti-T. gondii antibodies in hemodialysis patients with chronic renal failure. We undertook a prospective study of our maintenance hemodialysis patients to determine whether these sources posed a risk for transmission of T. gondii. Methods: This study was carried out on patients undergoing regular hemodialysis in the dialysis units (Hemodialysis Center of Antakya State Hospital, Emir Hemodialysis Center and Antakya Hemodialysis Center, Hatay, Turkey) between January 2004 and June 2004. Two hundred and fifty-five hemodialysis patients and 50 healthy controls were studied for the prevalence of anti-T. gondii antibodies by enzyme-linked immunosorbent assay. Results: Anti-immunoglobulin G (IgG) and immunoglobulin M (IgM) T. gondii antibodies positivity were found to be 195 (76.5%) of the 255 hemodialysis patients and 24 (48%) of the 50 control subjects. The difference between them was statistically significant (p < 0.05). In addition, an increase of the seropositivity rate was detected with increasing length of time on hemodialysis treatment, indicating a statistically significant difference between these 2 parameters (p < 0.05). Conclusion: These findings confirm a high prevalence of toxoplasma infection in hemodialysis patients. These patients are a risk group for toxoplasma infection. Moreover, it is recommended that hemodialysis patients who are susceptible to toxoplasma infections should be identified by T. gondii IgG and IgM specific serological tests. Therefore, patients undergoing hemodialysis should be screened for toxoplasma before dialysis to prevent the dissemination of this infection through the hemodialysis procedure.en_US
dc.identifier.endpage1382en_US
dc.identifier.issn0379-5284
dc.identifier.issue9en_US
dc.identifier.pmid16155651en_US
dc.identifier.scopus2-s2.0-26944435481en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1378en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/13851
dc.identifier.volume26en_US
dc.identifier.wosWOS:000232566300008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSaudi Med Jen_US
dc.relation.ispartofSaudi Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleAnti-Toxoplasma gondii antibodies in hemodialysis patients receiving long-term hemodialysis therapy in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu